Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

被引:0
|
作者
Li, Qingsong [1 ,2 ,3 ]
Liang, Na [1 ,2 ,3 ]
Ouyang, Weiwei [1 ,2 ,3 ]
Su, Shengfa [1 ,2 ,3 ]
Ma, Zhu [1 ,2 ]
Geng, Yichao [1 ,2 ,3 ]
Hu, Yinxiang [1 ,2 ,3 ]
Li, Huiqin [1 ,2 ]
Lu, Bing [1 ,2 ,3 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Clin Med Coll, Teaching & Res Dept Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
关键词
Time; Non-small cell lung cancer (NSCLC); EGFR-TKIs; Primary tumor radiotherapy; Overall survival; TYROSINE KINASE INHIBITORS; OPEN-LABEL; PHASE-III; ADENOCARCINOMA HISTOLOGY; CONCURRENT CHEMOTHERAPY; MAINTENANCE THERAPY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; RADIATION-THERAPY; GEFITINIB;
D O I
10.1186/s12885-024-12826-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. Patients and methods In total, 238 patients with EGFR-TKIs and OS >= 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it. The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 - 30(<30 days), R30 - PD(>= 30 days and disease stable), and R-PD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. Results The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3-33.7) for the R group and 22 months(95% CI: 20.4-23.6) for the D group (chi(2) = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS. Among the four groups, The R30 - PD appeared to have the best OS (D, chi(2) = 19.307, p<0.001;R0 - 30, chi(2) = 11.687, p = 0.01; R-PD, chi(2) = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 - PD group had a significant long-term OS. The incidence of radiation pneumonitis >= grade 2 was17.3%(n = 19)and radiation esophagitis >= grade 2 was observed in 32 patients(29.1%). Conclusions Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 - PD)of primary tumour radiotherapy may be the best choice. Premature radiotherapy(R0 - 30) and radiotherapy after disease progression (R-PD)may not be reasonable for long-term OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [32] Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials
    Lai, Xiaoming
    Zeng, Jinlin
    Xiao, Zhijun
    Xiao, Junlan
    MEDICINE, 2024, 103 (23) : e38277
  • [33] Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
    Aguiar, Filipa
    Fernandes, Gabriela
    Queiroga, Henrique
    Machado, Jose Carlos
    Cirnes, Luis
    Moura, Conceicao Souto
    Hespanhol, Venceslau
    ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (01): : 10 - 17
  • [34] Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
    Kubo, Naoki
    Harada, Taishi
    Shiraishi, Yoshimasa
    Nosaki, Kaname
    Nakagaki, Noriaki
    Takeshita, Masafumi
    Ouchi, Hiroshi
    Iwama, Eiji
    Tanaka, Kentaro
    Okamoto, Isamu
    Sasaki, Hiroyuki
    Nakanishi, Yoichi
    ANTICANCER RESEARCH, 2019, 39 (02) : 671 - 677
  • [35] Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
    Li, Fang
    Zhu, Tengjiao
    Cao, Baoshan
    Wang, Jiadong
    Liang, Li
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 184 - 192
  • [36] Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
    Wang, Fang
    Diao, Xia-Yao
    Zhang, Xiao
    Shao, Qiong
    Feng, Yan-Fen
    An, Xin
    Wang, Hai-Yun
    CANCER COMMUNICATIONS, 2019, 39
  • [37] Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer
    Inomata, Minehiko
    Shimokawa, Kazuki
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Yamada, Toru
    Miwa, Toshiro
    Hayashi, Ryuji
    Kashii, Tatsuhiko
    Matsui, Shoko
    Tobe, Kazuyuki
    ANTICANCER RESEARCH, 2016, 36 (09) : 4951 - 4954
  • [38] Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Sakharkar, Prashant
    Kurup, Sonali
    Deb, Subrata
    Assaad, Kaitlin
    Gesinski, Dayna
    Gayle, Erysa J.
    CANCERS, 2024, 16 (06)
  • [39] Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis
    Zhang, Yaxiong
    Sheng, Jin
    Yang, Yunpeng
    Fang, Wenfeng
    Kang, Shiyang
    He, Yang
    Hong, Shaodong
    Zhan, Jianhua
    Zhao, Yuanyuan
    Xue, Cong
    Ma, Yuxiang
    Zhou, Ting
    Ma, Shuxiang
    Gao, Fangfang
    Qin, Tao
    Hu, Zhihuang
    Tian, Ying
    Hou, Xue
    Huang, Yan
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    ONCOTARGET, 2016, 7 (15) : 20093 - 20108
  • [40] Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
    Cheng, Daoan
    Ge, Kele
    Yao, Xue
    Wang, Banglu
    Chen, Rui
    Zhao, Weiqing
    Fang, Cheng
    Ji, Mei
    FRONTIERS IN IMMUNOLOGY, 2023, 14